Lenalidomida Stada

Lenalidomide, the active ingredient in Lenalidomida Stada, is an immunomodulatory agent (IMiD) presented as an oral tablet for systemic use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide with reliable logistics.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic clones. - Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: provides disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Rash: skin redness or itching. - Nausea: feeling of sickness that may lead to vomiting.

Serious or Rare Side Effects: - Thromboembolic events: blood clots such as deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

When prescribing Lenalidomida Stada, clinicians should consider several safety and handling precautions. - Pregnancy risk: avoid use in pregnant women; a risk management program is required. - Thrombosis prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests regularly. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may lower lenalidomide exposure (e.g., rifampin, carbamazepine). - Anticoagulants: increased risk of bleeding when combined with warfarin or direct oral anticoagulants. - Immunosuppressants: may enhance immunosuppression, raising infection risk.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: may increase plasma levels (e.g., verapamil, quinidine). - NSAIDs: can exacerbate renal toxicity. - Vaccines: live attenuated vaccines may be less effective; avoid during therapy.